Physician profile
Kara Izzo
NPI 1093407066
$3,104.42
in general payments reported to CMS, 2019-2025
39 companies · $1,854 in 2025
The $1,854 reported for 2025 was more than what 95% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $166 · 2024: $1,084 · 2025: $1,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,104.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $347.52 | 2024-2025 | |
| Ucb, INC. | $320.94 | 2023-2025 | Rystiggo, Fintepla, Zilbrysq |
| Abbvie INC. | $207.13 | 2024-2025 | |
| Eisai INC. | $191.30 | 2024-2025 | |
| Octapharma USA, INC. | $191.28 | 2024-2025 | Panzyga |
| Tg Therapeutics, INC. | $149.14 | 2024-2025 | |
| Genentech USA, INC. | $125.17 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Teva Pharmaceuticals USA, INC. | $124.38 | 2024-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Biogen, INC. | $117.56 | 2025 | Tysabri, Vumerity |
| Lundbeck LLC | $106.55 | 2024-2025 | Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $99.81 | 2024-2025 | Hyqvia |
| Vanda Pharmaceuticals INC. | $96.27 | 2025 | Ponvory |
| Alexion Pharmaceuticals, INC. | $91.83 | 2023-2025 | Ultomiris |
| Scilex Pharmaceuticals INC. | $88.57 | 2023-2025 | Ztlido |
| Genzyme Corporation | $76.88 | 2024-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $74.42 | 2024-2025 | Vyvgart Hytrulo |
| Cycle Pharmaceuticals INC | $56.94 | 2025 | Tascenso Odt |
| Mallinckrodt Hospital Products INC. | $54.51 | 2024-2025 | Acthar |
| Si-Bone, INC. | $50.91 | 2024 | |
| Amneal Pharmaceuticals LLC | $39.06 | 2023 | Lyvispah |
| Life Molecular Imaging LTD | $38.28 | 2024-2025 | Neuraceq |
| Astrazeneca Pharmaceuticals LP | $38.13 | 2024 | Wainua, Andexxa |
| Otsuka America Pharmaceutical, INC. | $36.27 | 2024-2025 | Rexulti, Nuedexta |
| Tanabe Pharma America, INC. | $35.79 | 2024-2025 | Radicava |
| Lilly USA, LLC | $35.04 | 2024 | Amyvid |
| Pfizer INC. | $34.32 | 2025 | |
| Vertos Medical, INC. | $32.02 | 2024 | Mild Device Kit |
| Ani Pharmaceuticals, INC. | $25.35 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $24.79 | 2024 | Uplizna |
| Sumitomo Pharma America, INC. | $23.70 | 2023 | Aptiom |
| Averitas Pharma INC. | $23.60 | 2025 | Qutenza |
| Neurocrine Biosciences, INC. | $23.40 | 2025 | |
| Tonix Medicines, INC. | $20.54 | 2025 | Zembrace Symtouch |
| Grifols USA, LLC | $18.99 | 2025 | Gamunex-C |
| Baxter Healthcare | $18.24 | 2024 | Floseal |
| Kedrion Biopharma, INC. | $17.23 | 2024 | Rhogam Ultra-Filtered Plus, Albuked, Gammaked |
| Theragen, INC. | $17.00 | 2024 | Actastim-S |
| Csl Behring | $16.41 | 2025 | Hizentra |
| Alnylam Pharmaceuticals INC. | $15.15 | 2023 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Izzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.